| Document |
Document Title |
|
WO/2024/085386A1 |
It has been identified that an alkynyl amino acid ester derivative preparation method using a photocatalytic reaction, according to the present invention, is simple and enables a linear, cyclic or chiral alkynyl amino acid ester derivati...
|
|
WO/2024/079128A1 |
The invention relates to compounds and their therapeutic use, said compounds having the formula (I): wherein, for example, Z is representing a (II) X is representing a NR5R6 group wherein R5 and R6 are hydrogen, R1 is represe...
|
|
WO/2024/074986A1 |
The present disclosure encompasses Ecopipam HBr, particularly crystalline Ecopipam HBr, or a solid state form of Ecopipam HBr.
|
|
WO/2024/067819A1 |
A piperidine-containing polycyclic derivative modulator, a preparation method therefor, and use thereof. In particular, the present invention relates to a compound represented by general formula (II-a), a preparation method therefor, a p...
|
|
WO/2024/067841A1 |
Provided are a benzazepine derivative, a conjugate containing same, and use thereof. Provided is an antibody-immunostimulatory conjugate represented by formula (I) or a pharmaceutically acceptable salt thereof. The benzazepine derivative...
|
|
WO/2024/051590A1 |
The present invention relates to a salt type and crystal form of a benzazepine fused ring compound and use thereof, and in particular to a maleate of a compound represented by formula (I), the structure of the maleate being represented b...
|
|
WO/2024/044813A1 |
The present invention relates to novel fluoroallylamine sulfone derivatives that are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for the treatment of a variety of indications, e.g., fibrosis, cancer an...
|
|
WO/2024/030736A1 |
Processes and facilities for producing several types of recycled content organic chemical compounds from waste plastic. Processing schemes are described herein for converting waste plastic (or hydrocarbon having recycled content derived ...
|
|
WO/2024/022434A1 |
The present application relates to a substituted pyridocycloheptane derivative, a preparation method therefor, and use of a pharmaceutical composition comprising the derivative or a deuterated derivative in medicine. In particular, the p...
|
|
WO/2024/024833A1 |
Provided are: a resin composition containing a cyclized resin precursor and a compound B in which the thermal decomposition start temperature at which an amine is generated is equal to or less than 200°C, as measured by means of the sim...
|
|
WO/2024/013196A1 |
The application provides a process for recovering purified ε-caprolactam from nylon 6-containing multi-component material which comprises the steps of a) providing a pre-concentrated nylon 6-containing material obtained by extraction, b...
|
|
WO/2024/011414A1 |
Disclosed in the present invention is a reaction method for secondary amine and o-diiodobenzene, comprising: reacting secondary amine with o-diiodobenzene in the presence of an alkali metal hydride or a Grignard reagent to complete the r...
|
|
WO/2024/000849A1 |
The present invention provides a method for synthesizing caprolactam by means of a Beckmann rearrangement reaction. In the method, by designing a special process route, selecting a specific solvent, and dissolving reactants with the solv...
|
|
WO/2024/000848A1 |
Provided in the present invention is a caprolactam synthesis method free of by-production of ammonium sulfate. By designing a special process route, selecting a specific solvent, and using cyclohexanone oxime as a raw material, a Beckman...
|
|
WO/2024/005032A1 |
In the production of crops in agriculture, horticulture, etc., due to factors such as damages caused by harmful bugs and the like still being significant and the emergence of harmful bugs resistant to existing drugs, there has been a dem...
|
|
WO/2023/240629A1 |
Provided are an ionic compound and a use thereof, a perovskite precursor solution, a perovskite material, a solar material, a solar cell, and an electrical device. The structure of the ionic compound is as shown in any one of formulas (1...
|
|
WO/2023/220526A1 |
The present disclosure provides conjugates and systems for modulating the activity of a ligand-binding polypeptide such as a D2 dopamine receptor. Such conjugates comprising an affinity agent, a linker; a photoisomerizable group and a li...
|
|
WO/2023/210623A1 |
The present invention is a novel haloalkyl sulfone anilide compound or a salt thereof, an herbicide composition including said compound or salt thereof, an herbicide method including a step for applying the herbicide composition, and a m...
|
|
WO/2023/199091A1 |
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. [Solving Means] A compound represented by the formula (I) is useful as an agent for the prophylaxis or treatment of narcolepsy.
|
|
WO/2023/196931A1 |
The present invention relates to compounds of formula (CX-II) or a pharmaceutically acceptable salt thereof, wherein Z is selected from the group consisting of a bond, (I), (II) and (III); each Y is independently selected from the group ...
|
|
WO/2023/187045A1 |
The present invention relates to a process for hydrolytically depolymerizing a polyamide prepared from ε-caprolactam and an apparatus for carrying out a process for hydrolytically depolymerizing a polyamide prepared from ε-caprolactam.
|
|
WO/2023/181054A1 |
The present invention relates to an improved process for the preparation for the stereo-specific preparation of Benazepril intermediate (3S)-3-[[(1S)-1- phenylethyl]amino]-1,3,4,5-tetrahydro-1-benzazepin-2-one of formula (IS). The steps ...
|
|
WO/2023/172415A1 |
Described herein are compounds useful as sweet flavor modifiers. Ingestible compositions that include one or more of these compounds in combination with a natural or artificial sweetener are also described. (I)
|
|
WO/2023/165943A1 |
The invention relates to novel compounds having the general formula (I), wherein R1, R10, Rx, Ry, Y, m, and n are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2023/156386A2 |
A compound comprising the following formula: wherein R1 is selected from H and a substituted or unsubstituted organic group; R2 may be present or absent and is independently selected from H and a substituted or unsubstituted organic grou...
|
|
WO/2023/154302A1 |
The invention provides macromolecule-supported compounds of Formula I comprising a macromolecule linked by conjugation to one or more 8-sulfonyl-2-aminobenzazepine derivatives. The invention also provides 8-sulfonyl-2-aminobenzazepine de...
|
|
WO/2023/154307A1 |
The invention provides immunoconjugates of Formula. (I) comprising an antibody linked by conjugation to one or more 8-sulfonyl-2-aminobenzazepine derivatives. The invention also provides 8-sulfonyl-2-aminobenzazepine derivative intermedi...
|
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
|
WO/2023/143386A1 |
The present invention relates to an aromatic ring-fused heterocyclic ring compound as a potassium channel regulator, and the preparation therefor and the use thereof. Specifically, the compound of the present invention has a structure as...
|
|
WO/2023/144337A1 |
The present invention provides an improved process for the recovery of ε-caprolactam from Nylon 6 comprising multi-component material, in particular multi-layered film. Further, the invention provides a plant configured to carry out the...
|
|
WO/2023/144338A1 |
The present invention provides a process and a plant for recovering purified ε-caprolactam from polyamide 6 comprising fishing nets, wherein the plant comprises a depolymerization section [B], a recovery section [C], and a purification ...
|
|
WO/2023/118968A2 |
Disclosed herein are methods of detecting xanthine oxidase expression in polycystic kidney disease, or methods of delaying the onset or treating polycystic kidney disease, or both. The inventors have made the remarkable discovery that ab...
|
|
WO/2023/094828A1 |
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein Ring A, R1, R2, R3, R4, Y1, Y2, Y3, Y4, a, t, u, and L are as defined herein. The compounds are antagonists of the resistant (R-type) v...
|
|
WO/2023/088420A1 |
The present disclose includes, among other things, compounds that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.
|
|
WO/2023/084441A1 |
The present invention relates to a process for producing ε-caprolactam by depolymerization of polycaprolactam (PA6) which comprises : a. contacting a composite material comprising PA6 and at least one fibrous reinforcing material with a...
|
|
WO/2023/074432A1 |
Provided is a green, energy-saving production method that achieves both re-utilization of a fossil resource and reduction of greenhouse gas emissions in a method for producing ε-caprolactam from a polyamide 6 resin composition. The pres...
|
|
WO/2023/072199A1 |
The present invention relates to the field of caprolactam production. Disclosed is a method for producing high-purity ε-caprolactam. The method comprises the following steps: (1) carrying out a gas-phase Beckmann rearrangement reaction ...
|
|
WO/2023/074441A1 |
Provided is a green, energy-conserving method for producing ε-caprolactam from a polyamide 6 resin composition, wherein said method achieves both fossil resource recycling and a reduction in greenhouse gas emissions. The present inventi...
|
|
WO/2023/074437A1 |
The present invention provides a recovery method with less energy consumption, the recovery method being capable of recovering ε-caprolactam and a polyamide 6 oligomer with high yield by depolymerization with use of a little water and s...
|
|
WO/2023/064164A1 |
The present invention is generally directed to dual inhibitors of poly (ADP-ribose) polymerase (PARP) and Wee1 useful in the treatment of diseases and disorders modulated by said enzymes and having the Formula (A): P-L-W (A), wherein P i...
|
|
WO/2023/040998A1 |
Provided herein are a series of compounds as potent inhibitors of cyclin-dependent kinase (CDK), or pharmaceutically acceptable salts thereof. Corresponding compositions are also provided.
|
|
WO/2023/025276A1 |
Disclosed in the present invention is a compound having a structure shown in general formula I, or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a solvate thereof. Further disclosed in the present invention are a...
|
|
WO/2023/285788A1 |
A process for preparing a compound of formula (I), or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula (I).
|
|
WO/2022/266363A1 |
Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: wherein R1, R2, R3a, R3b, R4, R5, and A are defined in the present disclosure. The compounds are potent inhibit...
|
|
WO/2022/265960A1 |
A method of preventing or treating neuronal damage in a patient being administered a therapy that can cause nerve damage, comprising administering to said patient an effective amount of a neuroprotective compounds for Formula 1, (I) wher...
|
|
WO/2022/261524A1 |
The present disclosure provides phosphonate-containing heterocycle compounds with TYK2 kinase inhibitory activity, pharmaceutical compositions comprising the same, and applications thereof. The present disclosure provides compounds of Fo...
|
|
WO/2022/250108A1 |
The present invention pertains to a therapeutic agent or preventative agent against diseases involving an orexin receptor, particularly an orexin type-2 receptor, the agent containing a novel compound having a urea skeleton, or a pharmac...
|
|
WO/2022/242724A1 |
The present application relates to a nitrogen-containing compound, a conjugate containing said compound, and an application thereof. Specifically, the present application provides a compound represented by formula (I), a solvate thereof,...
|
|
WO/2022/243097A1 |
A process to produce N-vinyl compounds by homogeneous catalysis, wherein acetylene is re-acted with a compound having at least one nitrogen bearing a substitutable hydrogen residue in a liquid phase in the presence of at least one phosph...
|
|
WO/2022/228413A1 |
Disclosed in the present invention are an RIPK1 inhibitor for inhibiting programmed cell death and a preparation method therefor. The RIPK1 inhibitor of the present invention is as represented by general formula I, wherein X, Y, Z, L, R1...
|
